Jci_page_head_homepage_01 Jci_page_head_homepage_02
Thierry Touvier, Françoise Conte-Auriol, Olivier Briand, Céline Cudejko, Réjane Paumelle, Sandrine Caron, Eric Baugé, Yves Rouillé, Jean-Pierre Salles, Bart Staels, Bernard Bailleul
Published in Volume 119, Issue 12
J Clin Invest. 2009; 119(12):3830–3838 doi:10.1172/JCI34997
Abstract | Full text | PDF
Options: View larger image (or click on image)
Medium
Figure 7
LEPROT/LEPROTL1 double-transgenic mice display an exacerbated growth defect phenotype and liver GH resistance.

(A) Picture of 10-week-old male WT and LEPROT/LEPROTL1 Tg mice. (B) Liver Igf1 and Als mRNA expression levels after 6 hours of fasting in WT (n = 6) and LEPROT/LEPROTL1-Tg mice (n = 4). (C) Specific cell-surface hGH binding (n = 3 mice per group) and (D) Socs2 mRNA levels (with or without GH) in primary hepatocytes isolated from LEPROT-Tg and LEPROT/LEPROTL1-Tg mice. *P < 0.05, LEPROT/LEPROTL1-Tg versus WT (B) or versus LEPROT-Tg (C and D), Wilcoxon’s t test. Data shown are mean ± SD.